<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04836871</url>
  </required_header>
  <id_info>
    <org_study_id>DFPPv1.0</org_study_id>
    <nct_id>NCT04836871</nct_id>
  </id_info>
  <brief_title>Double Filtration Plasmapheresis Combined With Chemotherapy</brief_title>
  <official_title>Clinical Research of Double Filtration Plasmapheresis Combined With Chemotherapy to Remove M Protein in Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fuling Zhou</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zhongnan Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluation of double filtration plasmapheresis combined with chemotherapy for the treatment&#xD;
      of abnormalities of M protein or renal function due to the multiple myeloma.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 15, 2021</start_date>
  <completion_date type="Anticipated">October 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2024</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>M protein clearance rate</measure>
    <time_frame>1hour</time_frame>
    <description>before each treatment of Double filtration plasmapheresis (DFPP)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>M protein clearance rate</measure>
    <time_frame>1hour</time_frame>
    <description>after each treatment of DFPP</description>
  </primary_outcome>
  <primary_outcome>
    <measure>creatinine clearance rate</measure>
    <time_frame>1hour</time_frame>
    <description>before each treatment of DFPP</description>
  </primary_outcome>
  <primary_outcome>
    <measure>creatinine clearance rate</measure>
    <time_frame>1hour</time_frame>
    <description>after each treatment of DFPP</description>
  </primary_outcome>
  <primary_outcome>
    <measure>albumin concentration</measure>
    <time_frame>1hour</time_frame>
    <description>before each treatment of DFPP</description>
  </primary_outcome>
  <primary_outcome>
    <measure>albumin concentration</measure>
    <time_frame>1hour</time_frame>
    <description>after each treatment of DFPP</description>
  </primary_outcome>
  <primary_outcome>
    <measure>serum-free light chain levels</measure>
    <time_frame>1hour</time_frame>
    <description>before each treatment of DFPP</description>
  </primary_outcome>
  <primary_outcome>
    <measure>serum-free light chain levels</measure>
    <time_frame>1hour</time_frame>
    <description>after each treatment of DFPP</description>
  </primary_outcome>
  <primary_outcome>
    <measure>blood urea nitrogen</measure>
    <time_frame>1hour</time_frame>
    <description>before each treatment of DFPP</description>
  </primary_outcome>
  <primary_outcome>
    <measure>blood urea nitrogen</measure>
    <time_frame>1hour</time_frame>
    <description>after each treatment of DFPP</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Platelet concentrations</measure>
    <time_frame>1hour</time_frame>
    <description>before each treatment of DFPP</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Platelet concentrations</measure>
    <time_frame>1hour</time_frame>
    <description>after each treatment of DFPP</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>Double filtration plasmapheresis (DFPP) combined with chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>DFPP combined with chemotherapy</intervention_name>
    <description>Double filtration plasmapheresis combined with chemotherapy</description>
    <arm_group_label>Double filtration plasmapheresis (DFPP) combined with chemotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Multiple myeloma patients who are diagnosed by bone marrow morphology and immunology&#xD;
&#xD;
          -  Patients with stable condition after conventional treatment&#xD;
&#xD;
          -  Patients with renal insufficiency or abnormal M protein&#xD;
&#xD;
          -  Patients over 18 years of age&#xD;
&#xD;
          -  Liver function: blood bilirubin ≤ 35μmol/L, enzymes aspartate transaminase (AST)/aka&#xD;
             alanine aminotransferase (ALT) is less than 2 times the upper limit of normal&#xD;
&#xD;
          -  Normal heart function&#xD;
&#xD;
          -  Physical condition score 0-2 level (ECOG score)&#xD;
&#xD;
          -  Obtain an informed consent form signed by the patient or family member&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Allergies or obvious contraindications to any of the drugs involved in the plan&#xD;
&#xD;
          -  Severe heart disease, including myocardial infarction and cardiac insufficiency.&#xD;
&#xD;
          -  Suffering from other organ malignancies&#xD;
&#xD;
          -  Active tuberculosis patients and HIV-positive patients&#xD;
&#xD;
          -  At the same time suffering from other blood system diseases&#xD;
&#xD;
          -  Pregnant or lactating women&#xD;
&#xD;
          -  Able to understand or follow the research plan&#xD;
&#xD;
          -  Past history of intolerance or allergy to similar drugs&#xD;
&#xD;
          -  Patients under 18 years of age&#xD;
&#xD;
          -  Participating in other clinical researchers at the same time&#xD;
&#xD;
          -  There are any other circumstances that hinder the progress of the research&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Zhongnan Hospital of Wuhan University</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430071</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fuling Zhou, director</last_name>
      <phone>+86-02767813137</phone>
      <email>zhoufuling@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>March 7, 2021</study_first_submitted>
  <study_first_submitted_qc>April 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 8, 2021</study_first_posted>
  <last_update_submitted>July 10, 2021</last_update_submitted>
  <last_update_submitted_qc>July 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Zhongnan Hospital</investigator_affiliation>
    <investigator_full_name>Fuling Zhou</investigator_full_name>
    <investigator_title>Head, Division of Hematology; Professor of Hematology; Doctoral advisor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

